SequelSEC

PRO DEX INC PDEX

Surgical & Medical Instruments & Apparatus · CIK 0000788920 · Fiscal year ends 0630

Revenue
$77.55M
Fiscal year ended 2026-06-30
Operating income
$12.99M
Fiscal year ended 2026-06-30
Free cash flow
$6.76M
Fiscal year ended 2026-06-30

PRO DEX INC (PDEX) reported revenue of $77.55M and net income of $13.66M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from PRO DEX INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

PRO DEX INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$77.55M
Cost of revenue$53.21M
Gross profit$24.33M
Operating income$12.99M
Net income$13.66M
Research & development$3.35M
Weighted-average diluted sharesUnavailable
Pretax income$18.02M
Income tax expense$4.35M
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

PRO DEX INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$8.19M
Total assets$74.51M
Current assets$53.25M
Total liabilities$26.88M
Current liabilities$12.98M
Total equity incl. NCI$47.63M
Temporary (mezzanine) equityUnavailable
Inventory$21.46M
Accounts receivable$21.20M
Goodwill$6.52M
Long-term debt$17.51M
Accounts payable$4.26M

Cash flow

PRO DEX INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$7.24M
Capital expenditures$483.00K
Investing cash flow$3.91M
Financing cash flow-$3.38M
Net change in cashUnavailable
Stock-based compensation$688.00K
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$1.39M

Derived

PRO DEX INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$6.76M
Gross margin31.4%
Operating margin16.8%
FCF margin8.7%
SBC / revenue0.9%
Current ratio4.10x
Revenue YoY growth16.4%
Net margin17.6%
R&D / revenue4.3%
CapEx / revenue0.6%
Long-term debt / equity0.37x
Effective tax rate24.2%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PDEX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-K · Filed 2026-09-03View SEC filing
10-Q · Filed 2026-04-30View SEC filing
10-Q · Filed 2026-01-29View SEC filing
10-Q · Filed 2025-10-30View SEC filing
10-K · Filed 2025-09-04View SEC filing
10-Q · Filed 2025-05-01View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.